Evidence map›Paper›PMID 39524611›Full record

ArticleToxicology research2024

Biocompatible Naringin loaded low molecular peptide Nanogels are effective against human melanoma cells.

Jülide Secerli, Burcu Karayavuz, Rahime Aksoy, Hakan Erdoğan, Merve Güdül Bacanlı

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jülide SecerliGülhane Faculty of Pharmacy Department of Pharmaceutical Toxicology, University of Health Sciences Turkey, 06018 Ankara, Türkiye.ORCID https://orcid.org/0000-0002-4875-2266
Burcu KarayavuzGülhane Faculty of Pharmacy Department of Pharmaceutical Chemistry, University of Health Sciences Turkey, 06018 Ankara, Türkiye.ORCID https://orcid.org/0000-0001-9631-2575
Rahime AksoyFaculty of Medicine, Department of Hematology, Ankara University, 06800 Ankara, Türkiye.ORCID https://orcid.org/0000-0001-8433-3627
Hakan ErdoğanGülhane Faculty of Pharmacy Department of Analytical Chemistry, University of Health Sciences Turkey, 06018 Ankara, Türkiye.ORCID https://orcid.org/0000-0002-7791-7445
Merve Güdül BacanlıGülhane Faculty of Pharmacy Department of Pharmaceutical Toxicology, University of Health Sciences Turkey, 06018 Ankara, Türkiye.ORCID https://orcid.org/0000-0001-8757-0572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma, a type of cancer, has the ability to metastasize and can be fatal. The lack of success in the treatment of melanoma with chemotherapeutic agents and the side effects have led to the search for new agents. Moreover, developing systems that will provide reduce side effects by using biocompatible carriers, may be beneficial. Naringin (NAR), from

Indexed as

AnticancerAnti-inflammatoryBioinspiredFmocMelanocyteTyrosine

Identifiers

PMID39524611
PMCPMC11542622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.